Apatinib Combined With Vinorelbine for Non-driver Gene Mutation Non-small Cell Lung Cancer

the Effectiveness and Safety Study on Apatinib Combined With Vinorelbine Used for Driver Gene Mutation Negative Third-line and Third-line Post Progression Advanced Non-small Cell Lung Cancer

The purpose of this study is to assess the safety and effectiveness of Apatinib Combined With Vinorelbine Used for Driver Gene Mutation Negative Third-line and Third-line Posterior Advanced Non-small Cell Lung Cancer

This efficacy and safety research plan to explore the use of Apatinib combined with Vinorelbine to driven gene mutation negative three line and three line later non-small cell lung cancer.According to the result of TAX317,the investigators expect the effective rate is 20% and 80% of degree of assurance.Single arm bilateral experiment's sample size is calculated 27, according to 10% censoring,the expected sample size is 30.

Inclusion Criteria:

• 18，Pathologically proven non small cell lung cancer

  • Adenocarcinoma，No-drive gene mutaion (EGFR、ALK、ROS1） by NGS
  • Squamous cell carcinoma，no gene detection
  • Progress after second line
  • PS score >2

Exclusion Criteria:

• Patients received apatinib or Vinorelbine treatment before
• EGFR, ALK or ROS1 mutation
• Patients with contraindication of chemotherapy
• Pregnant or breast feeding women